PhenoSense® Integrase is the first and only commercially available, phenotypic resistance assay to measure susceptibility to integrase inhibitors.
Features and Benefits
- Validated to be accurate, precise, sensitive, reproducible, and robust in the measurement of susceptibility to integrase inhibitors1
- Used in clinical studies of raltegravir (Isentress®) to identify and characterize raltegravir-resistant viruses in patients with treatment failure
- Based on Monogram's proven PhenoSense® platform technology and dedication to understanding HIV-1 drug resistance
- Together with PhenoSense GT® and PhenoSense Entry®, PhenoSense® Integrase provides the most complete picture of resistance to antiretroviral medications
- Because it provides a direct measure of a patient's HIV-1susceptibility to integrase inhibitors, PhenoSense® Integrase is providing phenotypic resistance analysis in a variety of clinical trials (Table 1)
PhenoSense® Integrase is also being used with several other compounds in Phase I and II clinical trials
Table 1.
PhenoSense® Integrase Clinical Trial Use
|
Download Sample PhenoSense Integrase Report |